Aclaris Therapeutics, Inc. cotiza a 3.60 USD y tiene una capitalización bursátil de $530M. En los últimos 12 meses ha facturado $8M con un margen de flujo de caja libre del -603.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody i…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.15 | $-0.15 | $-0.16 |
| Estimado | $-0.16 | $-0.16 | $-0.16 | $-0.14 |
| Sorpresa | — | +6.3% | +6.3% | -14.3% |
| Métrica | ACRS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 73.3% | 57.0% | +16.2% |
| Operating Margin | -975.9% | -38.6% | -937.3% |
| Net Margin | -829.6% | -33.6% | -796.0% |
| FCF Margin | -603.4% | -13.9% | -589.6% |
| ROE | -63.0% | -40.4% | -22.6% |
| ROA | -40.5% | -32.0% | -8.5% |
| Current Ratio | 3.36 | 2.84 | +0.52 |
| Debt / Equity | — | 0.28 | — |